Related Experiment Video
Updated: Jun 15, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma
Melissa L Diamantis1, Susan Y Chon
1The University of Texas Medical School, Houston, TX 77030, USA. Melissa.L.Diamantis@uth.tmc.edu
Abstract:
Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis and is used for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and other solid tumors. Various dermatologic side effects have been reported, most notably a hand-foot-skin reaction (HFSR). This is a case of a sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. This patient also developed cutaneous squamous cell carcinoma and HFSR in association with sorafenib. To the authors' knowledge, a psoriasiform eruption due to sorafenib has not been reported in the literature and has important therapeutic implications.
Insights
Sorafenib, a multikinase inhibitor, can cause a rare psoriasiform eruption, distinct from the common hand-foot-skin reaction. This case highlights a novel dermatologic side effect of sorafenib in thyroid cancer patients.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Sorafenib is a multikinase inhibitor used to treat advanced renal cell carcinoma, hepatocellular carcinoma, and other solid tumors.
- Dermatologic side effects are common with sorafenib, with hand-foot-skin reaction (HFSR) being the most frequently reported.
- Sorafenib targets tumor cell proliferation and angiogenesis, crucial processes in cancer progression.
Observation:
- A patient with metastatic thyroid carcinoma developed a psoriasiform eruption while undergoing sorafenib treatment.
- This patient also experienced hand-foot-skin reaction (HFSR) and cutaneous squamous cell carcinoma concurrently.
- The psoriasiform eruption presented as a distinct dermatologic manifestation during sorafenib therapy.
Findings:
- The case presents a sorafenib-induced psoriasiform eruption, a previously unreported adverse reaction in the medical literature.
- This specific eruption is differentiated from the more common hand-foot-skin reaction (HFSR) associated with sorafenib.
- The patient's concurrent development of squamous cell carcinoma adds complexity to the observed cutaneous effects.
Implications:
- This finding expands the known spectrum of sorafenib-induced dermatologic toxicities.
- Awareness of this psoriasiform eruption is crucial for clinicians managing patients on sorafenib therapy.
- Early recognition and management of this adverse event may be necessary to optimize patient treatment outcomes and quality of life.
